MedTrace Logo

Glucosamine Sulphate and Ginkgo Biloba as Antifungal Activity for Treating Tinea Pedis

NCT02882438 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2019-10-10

No results posted yet for this study

Summary

Tinea Pedis infected the feet of about 20-25% of the world population. Tinea Pedis is a fungal infection of the feet and it is easily spread. Oral therapy is usually used for chronic conditions or when topical treatment has failed. The aim of this study is to prove the antifungal and antibacterial activity of Ginko Biloba (GKB) \& Glucosamine (GL) as separate material or both in combination.

Conditions

  • Foot Infection Tinea Pedis

Interventions

DRUG

infected group

Ginkgo Biloba in different dosage forms

DRUG

control group

placebo without Ginkgo Biloba

Sponsors & Collaborators

  • Ahmed A. H. Abdellatif

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2020-09-30
Completion
2022-10-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02882438 on ClinicalTrials.gov